| Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development M Frantzi, A Bhat, A Latosinska Clinical and translational medicine 3, 1-22, 2014 | 154 | 2014 |
| Comparative analysis of label-free and 8-Plex iTRAQ approach for quantitative tissue proteomic analysis A Latosinska, K Vougas, M Makridakis, J Klein, W Mullen, M Abbas, ... PloS one 10 (9), e0137048, 2015 | 117 | 2015 |
| Peptidomics and proteomics based on CE‐MS as a robust tool in clinical application: The past, the present, and the future A Latosinska, J Siwy, H Mischak, M Frantzi Electrophoresis 40 (18-19), 2294-2308, 2019 | 112 | 2019 |
| Proteomics and metabolomics for AKI diagnosis D Marx, J Metzger, M Pejchinovski, RB Gil, M Frantzi, A Latosinska, ... Seminars in nephrology 38 (1), 63-87, 2018 | 90 | 2018 |
| Developing proteomic biomarkers for bladder cancer: towards clinical application M Frantzi, A Latosinska, L Flühe, MC Hupe, E Critselis, MW Kramer, ... Nature Reviews Urology 12 (6), 317-330, 2015 | 85 | 2015 |
| Proteomics biomarkers for solid tumors: Current status and future prospects I Belczacka, A Latosinska, J Metzger, D Marx, A Vlahou, H Mischak, ... Mass spectrometry reviews 38 (1), 49-78, 2019 | 81 | 2019 |
| Proteomics in drug development: the dawn of a new era? M Frantzi, A Latosinska, H Mischak PROTEOMICS–Clinical Applications 13 (2), 1800087, 2019 | 62 | 2019 |
| Comparison of depletion strategies for the enrichment of low-abundance proteins in urine S Filip, K Vougas, J Zoidakis, A Latosinska, W Mullen, G Spasovski, ... PLoS One 10 (7), e0133773, 2015 | 57 | 2015 |
| Urinary peptides in heart failure: a link to molecular pathophysiology T He, M Mischak, AL Clark, RT Campbell, C Delles, J Díez, G Filippatos, ... European Journal of Heart Failure 23 (11), 1875-1887, 2021 | 50 | 2021 |
| Proteome‐based classification of nonmuscle invasive bladder cancer R Stroggilos, M Mokou, A Latosinska, M Makridakis, V Lygirou, ... International Journal of Cancer 146 (1), 281-294, 2020 | 49 | 2020 |
| Value of urine peptides in assessing kidney and cardiovascular disease A Latosinska, J Siwy, S Faguer, J Beige, H Mischak, JP Schanstra PROTEOMICS–Clinical Applications 15 (1), 2000027, 2021 | 44 | 2021 |
| Analytical performance of ELISA assays in urine: one more bottleneck towards biomarker validation and clinical implementation D Chatziharalambous, V Lygirou, A Latosinska, K Stravodimos, A Vlahou, ... PLoS One 11 (2), e0149471, 2016 | 43 | 2016 |
| Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect? PE Nikolaou, N Mylonas, M Makridakis, M Makrecka-Kuka, A Iliou, ... Basic research in cardiology 117 (1), 27, 2022 | 42 | 2022 |
| Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease V Lygirou, A Latosinska, M Makridakis, W Mullen, C Delles, JP Schanstra, ... Journal of Translational Medicine 16, 1-12, 2018 | 42 | 2018 |
| Reproducibility evaluation of urinary peptide detection using CE-MS E Mavrogeorgis, H Mischak, A Latosinska, J Siwy, V Jankowski, ... Molecules 26 (23), 7260, 2021 | 39 | 2021 |
| Proteomics analysis of bladder cancer invasion: targeting EIF3D for therapeutic intervention A Latosinska, M Mokou, M Makridakis, W Mullen, J Zoidakis, V Lygirou, ... Oncotarget 8 (41), 69435, 2017 | 38 | 2017 |
| Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: focus on bladder cancer A Latosinska, M Frantzi, A Vlahou, H Mischak Proteomics–Clinical Applications 7 (11-12), 779-793, 2013 | 37 | 2013 |
| Urinary CE-MS peptide marker pattern for detection of solid tumors I Belczacka, A Latosinska, J Siwy, J Metzger, AS Merseburger, H Mischak, ... Scientific reports 8 (1), 5227, 2018 | 36 | 2018 |
| Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups S Siebert, D Porter, C Paterson, R Hampson, D Gaya, A Latosinska, ... Scientific reports 7 (1), 40473, 2017 | 34 | 2017 |
| Clinical proteomics for precision medicine: the bladder cancer case A Latosinska, M Frantzi, A Vlahou, AS Merseburger, H Mischak PROTEOMICS–Clinical Applications 12 (2), 1700074, 2018 | 33 | 2018 |
